Date: May 9, 2024
Attention: All Providers
Effective date: May 7, 2024
Call to action: Effective May 7, 2024, the Texas Health and Human Services (HHS) removed non-preferred status from generic linezolid suspension products. This is in response to the long term back order of the brand product Zyvox by the manufacturer.
The preferred status of the brand name Zyvox will not change to allow any current stock to be used.
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Please see below for the list of impacted drugs (of note, the approval is NDC-specific):
| Preferred Medication NDC | Preferred Medication | Type of Change | Effective Date |
| 00054031950 | LINEZOLID 100 MG/5 ML SUSP | Generic now preferred | May 9, 2024 |
| 31722086525 | LINEZOLID 100 MG/5 ML SUSP | Generic now preferred | May 9, 2024 |
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers